This message contains images. If you don't see images, click here to view.
Click here to advertise in this news brief.




Text Version  RSS  Subscribe  Unsubscribe  Archive  Media Kit October 17, 2014
Home    About AST    Education    Meetings & Events    Public Policy    Contact Us  

 

OPTN/UNOS guidance regarding Ebola
AST
The OPTN/UNOS Ad Hoc Disease Transmission Advisory Committee (DTAC), after careful review of information available from the Centers for Disease Control (CDC), is offering information to transplant centers and OPOs in light of the first case of Ebola virus disease (EVD) identified in the United States. While the risk of a person with previously undiagnosed EVD becoming an organ donor is thought to be extraordinarily low, the risk of transmitting the disease through transplantation is unstudied. Therefore, it is important for the transplant community to be aware of risk factors for this disease.
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE  



SOCIETY NEWS


Register for Webinars: WTC Highlights, KAS, and Changes in Healthcare
AST
WTC 2014 Clinical Highlights: Tuesday, Oct. 21, 2-3 p.m. EST. Register today at www.myAST.org/T3 - free for AST members. Whether you missed the World Transplant Congress or simply did not have time to catch all of the sessions, attend this webinar and get the important clinical highlights from the meeting.

Kidney Allocation System Changes: Strategies to Improve Recipient Readiness and Reduce Disparities: Tuesday, Nov. 4, 2-3 p.m. EST. Register today at www.myAST.org/T3 - free for AST members.

Changes in the Health Care Environment and Transplantation: Wednesday, Nov. 12, 2014, 2-3 p.m. EST. Register today at www.myAST.org/business - free for AST members. Understand changes in the healthcare environment and the effect of the ACA on transplantation.

Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Submit 2015 AST Board of Directors Nominations
AST
Nominations for qualified individuals to serve on the AST Board of Directors are now being solicited by the AST Governance Committee. Open positions include the President-Elect, Secretary, and three Councilor-at-Large positions. For a nomination to be seriously considered by the Governance Committee, the nominee should have had significant involvement in and service to the AST. Completed nominations must be submitted to the AST National Office by 5 p.m. Eastern time on Friday, Nov. 14, 2014. Review the criteria or submit a nomination.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article




OPTN/UNOS Resources: KAS readiness for patients and professionals
AST
The new kidney allocation system (KAS) begins Dec. 4, 2014. UNOS is hosting a virtual Town Hall on Oct. 23. Click here to register.

UNOS has also released a KAS training module to help educate both transplant professionals and patients waiting for a kidney transplant about the upcoming changes. Transplant professionals can use this module as a guide to talk to their patients about the upcoming changes and patients can also access it themselves to learn more about how the changes will impact them directly. View module now or visit the OPTN website for more information.

Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


UPCOMING EVENTS IN TRANSPLANTATION


Just two weeks left to submit your abstract for CEOT - Deadline Oct. 31
The Cutting Edge of Transplantation
Immunity and Inflammation: Engineering Cell, Gene, and Drug Therapies

AST
Feb. 5-7, 2015
Sheraton Wild Horse Pass – Chandler, Arizona 

The AST is now accepting abstracts for the Cutting Edge of Transplantation meeting. Don’t miss out on the opportunity to share your research with experts in transplantation. Submit your basic, clinical or translational abstract by Oct. 31. The AST will award a limited number of Young Innovator Award travel grants to the highest scoring abstracts submitted by emerging professionals in transplantation.

CEOT 2015 features over 30 talks from leading clinicians and scientists from academia and industry, plus rapid-fire abstract presentations, a poster session and multiple social events that allow you to connect with old friends and new. Program highlights include:
  • Tregs: What is the Promise of Cell Therapy Today?
  • Promising New Drugs in Other Fields: Best in Rheumatology, IBD & Cancer Immunology
  • The Approach to Repurposing Drugs
  • Novel Approaches to Modifying the Genome
  • Genetic Manipulation to “Supercharge” T Cells
  • Novel Therapeutic Strategies for Regenerative Medicine
  • Islet Cell Regeneration
Click here to register for CEOT 2015 and take advantage of early registration discounted rates! Or, learn more about this engaging meeting and view the preliminary program here.

Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


COMMITMENT TO CARE
Raptor's mission is to develop and commercialize life-altering therapeutics that treat rare, debilitating, and often fatal diseases.
LEARN MORE
Advertise here!

To find out how to feature your company in the AST eNewsletter and other advertising opportunities, Contact Tom Crist at 972-402-7724.
MORE


TRANSPLANT NEWS


Evaluation of solid organ transplant candidates for coronary artery disease
American Journal of Transplantation
Solid organ transplantation has increased in frequency in the United States, having evolved from an area of experimentation into accepted therapy for end-organ failure. As organ transplantation has become more common, the average age of transplant recipients has increased, thus increasing the potential for multiple comorbidities including coronary artery disease (CAD). CAD has been shown to be a major cause of morbidity and mortality in kidney, lung and liver transplant recipients. Identification of CAD in solid organ transplant candidates allows for stratification of short- and long-term risk, ensuring proper use of valuable allograft resources while guiding further patient management.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Pre-transplant donor HLA-specific antibodies: Characteristics causing detrimental effects on survival after lung transplantation
The Journal of Heart and Lung Transplantation
The impact of Luminex-detected HLA antibodies on outcomes after lung transplantation is unclear. Herein we have undertaken a retrospective study of pre-transplant sera from 425 lung transplants performed between 1991 and 2003. Pre-transplant sera, originally screened by complement-dependent cytotoxicity (CDC) assays, were retrospectively tested for the presence of HLA-specific antibodies using HLA-coated Luminex beads and C4d deposition on Luminex beads. The results were correlated with graft survival at 1 year.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


PRODUCT SHOWCASE
  UCLA Immunogenetics Center

The UCLA Immunogenetics Center (UIC) provides comprehensive testing for organ and tissue transplantation. Transplant testing has a long history at UCLA. HLA typing was pioneered here in the 1960's. The development of the microcytoxicity test in 1964 marked the beginning of international testing and standardization of HLA typing. The UCLA Immunogenetics Center has retained its leadership position in HLA research, and in the development of accompanying diagnostic testing. MORE
 


Subnormothermic preservation in Somah: A novel approach for enhanced functional Resuscitation of donor hearts for transplant
American Journal of Transplantation
Organ preservation at 4°C results in temporally irreversible injury to cellular structure and function. This study was designed to evaluate the possibility of storing hearts at ambient temperatures in novel organ preservation solution Somah to prevent damage and preserve optimum function by maintaining cellular energy over the temperature range of storage.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Drive-line infections and sepsis in patients receiving the HVAD system as a left ventricular assist device
The Journal of Heart and Lung Transplantation
Drive-line infections and sepsis lead to significant morbidity and even mortality in patients with ventricular assist devices (VADs). The HeartWare HVAD system is unique compared with other VAD systems in that it has a thin, flexible drive-line and is implanted directly into the pericardial space without the need for a pump pocket. This study reviewed 332 patients receiving the HVAD in the pivotal ADVANCE Bridge to Transplant (BTT) trial and Continued Access Protocol (CAP) to determine the incidence of drive-line infections and sepsis.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE




Kidney and liver transplantation in children with fibrocystic liver-kidney disease: Data from the US Scientific Registry of Transplant Recipients: 1990-2010
Pediatric Transplantation
The natural history and survival of children with fibrocystic liver-kidney disease undergoing solid organ transplantation have infrequently been described. We report outcomes in a cohort of US children with fibrocystic liver-kidney disease receiving solid organ transplants over 20 yr. Retrospective cohort study of pediatric transplant recipients with diagnoses of fibrocystic liver-kidney disease from 1/1990 to 3/2010, using data from the SRTR. Subjects were categorized by the first transplanted organ: LT, KT, or SLK. Primary outcomes were death, re-transplant, transplant of the alternate organ, or initiation of dialysis.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Health-related quality of life in pediatric intestinal transplantation
Pediatric Transplantation
This study aimed to determine HRQOL after pediatric intestinal transplantation. Thirty-four IT survivors from 1999 to 2012 were asked to complete age-specific HRQOL non-disease-specific questionnaires: TAPQOL (0–4 yr), KINDL-R (5–7 yr; 8–12 yr; 13–17 yr), and SF-36v2 (>18 yr), all validated with Spanish population. Primary caregiver completed a SF-36 questionnaire and CBI. Thirty-one participants were included. Median age was 10.2 yr (1–29) and time after transplant 4.4 yr (0–13).
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


TRENDING ARTICLES
Missed last week's issue? See which articles your colleagues read most.

    Impact of the lung allocation score on survival beyond 1 year (American Journal of Transplantation)
Risk of metabolic complications in kidney transplantation after conversion to mTOR inhibitor: A systematic review and meta-analysis (American Journal of Transplantation)
Impact of broader sharing on the transport time for deceased donor livers (Liver Transplantation)
Denatured class I human leukocyte antigen antibodies in sensitized kidney recipients: Prevalence, relevance, and impact on organ allocation (Transplantation)
Uniform donor risk interview forms available (AST)

Don't be left behind. Click here to see what else you missed.
 



AST eNews

Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Julie Bernhard, Executive Editor, 469.420.2647  
Contribute news


This edition of the AST eNews was sent to ##Email##. To unsubscribe, click here.

Recent issues
Oct. 10, 2014
Oct. 3, 2014
Sept. 26, 2014
Sept. 19, 2014






7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063